ImmuPharma plc is a drug discovery and development group in London, U.K. with operations in its subsidiaries in Mulhouse, France and Basle, Switzerland. The company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders . Each would represent a significant breakthrough in its field. The company also has a strong proprietary and collaborative drug development pipeline.

ImmuPharma was founded and is led by a management team with extensive experience in the international pharma industry, business and finance.

ImmuPharma plc is publicly listed in London and its shares trade under the symbol IMM (LSE:IMM or for Bloomberg IMM:LN).

Disclaimer and copyright notice